Kabra Drugs posts ₹92.74 cr revenue after a year of nil sales
The nano-cap drugmaker executed a new manufacturing strategy, swinging from a ₹1.08 cr loss to a ₹4.96 cr profit on a ₹92.74 cr topline.
— 1 earlier story on Kabra Drugs Ltd. →What's new
- Kabra Drugs reported ₹92.74 cr in FY26 revenue after zero sales in the prior year.
- Net profit was ₹4.96 cr, reversing a ₹1.08 cr loss in FY25.
- The turnaround is attributed to a new multi-sector manufacturing strategy.
Why this matters
The jump from nil revenue to ₹92.74 cr is a rare clean break from a prior operational standstill. For a company with a ₹59 cr market cap, that topline suddenly makes the equity value look inexpensive on a sales basis. The unmodified auditor opinion provides a basic level of credibility to these first-year numbers.
What we're watching
- Whether the new manufacturing strategy sustains revenue in FY27.
- The margin profile on this new business to judge profitability quality.
- Any follow-on capex or order disclosures to gauge scale.
The full read
Kabra Drugs was a ₹nil revenue company a year ago. It is now a ₹92.74 cr revenue company. The audited FY26 results show the firm, which has a market cap of just ₹59 cr, generated ₹92.74 cr in sales and a ₹4.96 cr net profit, reversing a prior-year loss of ₹1.08 cr. The turnaround is credited to a new multi-sector manufacturing strategy. For a nano-cap, that's a clean operational restart. The unmodified auditor opinion is the baseline confidence check. The bigger test is whether this new topline has staying power beyond a single year's execution.
Questions answered
- What drove Kabra Drugs' revenue surge in FY26?
- The company implemented a new multi-sector manufacturing strategy that generated ₹92.74 cr in revenue after the company recorded no sales in the prior fiscal year.
- How did the company's profitability change?
- Kabra Drugs swung from a net loss of ₹1.08 cr in FY25 to a net profit of ₹4.96 cr in FY26, a full-year swing of ₹6.04 cr.
- What is the scale of Kabra Drugs relative to its new results?
- The company has a market capitalisation of ₹59 cr. Its FY26 revenue of ₹92.74 cr is therefore larger than its entire market value.
- Did the auditors flag any issues with these results?
- No, the auditors issued an unmodified opinion. The board also confirmed no deviations in the use of capital during the period.
Story so far
All notes on KABRADG →- 29 May 2026 · 8:35 PM IST Kabra Drugs posts ₹92.74 cr revenue after a year of nil sales
- 1d ago Kabra Drugs books ₹92.74 cr revenue after a year of zero sales